^
Association details:
| Biomarker: | MSH3 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | PARP inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
Excerpt:
The in vitro drug screen of 93 CRC cell lines showed that PARP inhibition was active in a small subset of samples, based on the standardized and summed DSS (the PARP inhibitor sensitivity index) of four different PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib...31% (16/52) of the PARP inhibitor resistant cell lines also had homozygous mutations in at least one of these genes, including truncating mutations in MSH3 (HCA7), PTEN (LIM2405) or ATM (SW1222).
DOI:
https://doi.org/10.1016/j.ebiom.2020.102923
